Latest News

Add to Favorites Subscribe Share
newswise-fb-share-

Showing results

110 of 73

Article ID: 649411

ASCO to Hold Capitol Hill Briefing March 15 on The State of Cancer Care in America: 2016

American Society of Clinical Oncology (ASCO)

The State of Cancer Care in America: 2016 report, to be released on March 15 by the American Society of Clinical Oncology (ASCO), chronicles the current realities of the cancer care delivery system in the United States and examines trends in the oncology workforce and practice environment that are affecting patient care and access.

Released:
9-Mar-2016 1:05 PM EST
Open in New Tab
Comment

Law and Public Policy

Article ID: 646880

Maya Healers’ Conception of Cancer May Help Bridge Gap in Multicultural Settings Care

American Society of Clinical Oncology (ASCO)

Understanding and integrating patients’ cultural beliefs into cancer treatment plans may help improve their acceptance of and adherence to treatment in multicultural settings. Researchers examined traditional Maya healers’ understanding of cancer and published their findings online today in the Journal of Global Oncology.

Released:
27-Jan-2016 4:05 PM EST
Open in New Tab
Comment

Arts and Humanities

Article ID: 640910

Panel Recommends Primary Palliative Care Services for Medical Oncology Practices

American Society of Clinical Oncology (ASCO)

A new guidance statement from the American Society of Clinical Oncology and the American Academy of Hospice and Palliative Medicine is being presented for the first time at the 2015 Palliative Care in Oncology Symposium in Boston.

Released:
5-Oct-2015 5:05 PM EDT
Open in New Tab
Comment

Article ID: 640911

Innovative Collaboration Among Radiation Oncologists and Palliative Care Specialists Improves Care for Patients With Advanced Cancers

American Society of Clinical Oncology (ASCO)

An innovative service model that partners radiation oncology with palliative care leads to better results for patients, according to a new analysis. The model of care, established at Mount Sinai Medical Center in New York, is one of only a handful in the country.

Released:
5-Oct-2015 5:05 PM EDT
Open in New Tab
Comment

Article ID: 640908

New Evidence for a Strategy to Identify Patients Nearing the End of Life

American Society of Clinical Oncology (ASCO)

ALEXANDRIA, Va. – A new study provides compelling evidence that a simple tool can help predict which patients with cancer may be in their final year of life. The tool, known as the Surprise Question, was found to predict the risk of cancer death within one year better than factors such as cancer type or stage alone. This study will be presented at the upcoming 2015 Palliative Care in Oncology Symposium in Boston.

Released:
5-Oct-2015 5:00 PM EDT
Open in New Tab
Comment

Article ID: 630165

Early Evidence of Increase in Higher-Risk Prostate Cancers From 2011-2013

American Society of Clinical Oncology (ASCO)

An analysis of data on roughly 87,500 men treated for prostate cancer since 2005 finds a notable increase in higher-risk cases of the disease between 2011 and 2013. The study will be presented at the upcoming 2015 Genitourinary Cancers Symposium in Orlando.

Released:
23-Feb-2015 6:30 PM EST
Open in New Tab
Comment

Article ID: 630162

Adjuvant Sorafenib and Sunitinib Do Not Improve Outcomes in Locally Advanced Kidney Cancer

American Society of Clinical Oncology (ASCO)

Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years). The study will be presented at the upcoming 2015 Genitourinary Cancers Symposium in Orlando.

Released:
23-Feb-2015 6:05 PM EST
Open in New Tab
Comment

Article ID: 630163

Active Surveillance of Intermediate-Risk Prostate Cancer Associated With Decreased Survival

American Society of Clinical Oncology (ASCO)

An analysis of data on 945 patients with prostate cancer that is managed with active surveillance shows differences in outcomes depending on whether the patient was low or intermediate risk at diagnosis. Compared to patients with low-risk disease, those with intermediate-risk cancer (PSA >10ng/ml or Gleason score 7 or clinical stage T2b/2c) had a nearly four-fold higher chance of dying from prostate cancer within 15 years. The study will be presented at the upcoming 2015 Genitourinary Cancers Symposium in Orlando.

Released:
23-Feb-2015 6:00 PM EST
Open in New Tab
Comment

Article ID: 630164

Men Who Have Had Testicular Cancer Are More Likely to Develop Prostate Cancer, Although Overall Risk of Developing Aggressive Disease is Low

American Society of Clinical Oncology (ASCO)

A case-control study of close to 180,000 men suggests that the incidence of prostate cancer is higher among men with a history of testicular cancer (12.6 percent) than among those without a history of testicular cancer (2.8 percent). Men who have had testicular cancer were also more likely to develop intermediate- or high-risk prostate cancers. The study will be presented at the upcoming 2015 Genitourinary Cancers Symposium in Orlando.

Released:
23-Feb-2015 6:00 PM EST
Open in New Tab
Comment

Article ID: 630166

Androgen Receptor Abnormality May Not Be Associated With Primary Resistance to Taxane Chemotherapy

American Society of Clinical Oncology (ASCO)

ALEXANDRIA, Va. – Findings from a small prospective study suggest that androgen receptor V7 (or AR-V7) status does not significantly affect response to taxane chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). Treatment outcomes were largely similar for the 17 patients with AR-V7-positive prostate cancer and the 20 patients with AR-V7-negative disease included in this analysis. The study will be presented at the upcoming 2015 Genitourinary Cancers Symposium in Orlando.

Released:
23-Feb-2015 6:00 PM EST
Open in New Tab
Comment

Showing results

110 of 73

Chat now!